Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATIC: Oxidative-Stress-Reducing Strategy in Mild-to-Moderate Chronic Kidney Disease
NCT00384618Phase 4Terminated
- Sponsor
- Amsterdam University Medical Center
- Start
- May 2001
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of pravastatin, vitamin e, folic acid, pyridoxine and cyanocobalamin in cardiovascular disease (CVD) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Common carotid artery intima media thickness at 18 months and Brachial artery flow mediated vasodilatation at 18 months. Started May 2001; status: terminated.
02
Drugs
pravastatinvitamin efolic acidpyridoxinecyanocobalamin
03
Conditions
cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT00384618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00384618.